GEN Exclusives

More »

GEN News Highlights

More »
Apr 6, 2011

Cephalon Board Rejects Valeant’s $73 Per Share Unsolicited Takeover Bid

  • Cephalon’s board of directors has formally rejected Valeant Pharmaceuticals’ recent unsolicited $73 per share, $5.7 billion takeover bid. In a letter to Valeant’s CEO J. Michael Pearson, Cephalon CEO J. Kevin Buchi said an analysis by the firm and its independent financial advisors led to the conclusion that the Valeant proposal is both inadequate and not in the best interest of Cephalon’s shareholders.

    The Cephalon board states the offer was based on a "worst-case scenario"  valuation and represents virtually no premium to Cephalon’s 52-week high stock price. Moreover, Cephalon points out, the proposal ascribes “little or no value to Cephalon’s pipeline,” which the firm maintains is one of the broadest in the industry, with 10 late-stage product candidates targeting novel and best-in-class therapeutics. “The board believes that the Valeant nonbinding proposal is an opportunistic attempt by Valeant to shift this value to Valeant and its shareholders and away from Cephalon’s shareholders.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »